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Abstract
Objectives. To identify predictors of the specific (difference between treatment and placebo) and over-
all (change from baseline in treatment arm) treatment effects of topical NSAIDs in OA.
Methods. Randomized controlled trials (RCTs) of topical NSAIDs in OA were identified through system-
atic literature searching and inquiry to pharmaceutical companies. The raw, de-identified data were
analysed in one-stage individual patient data meta-analysis (IPD-MA). Negative values for treatment
effects (0–100 scale) indicate pain reduction.
Results. Of 63 eligible RCTs, 15 provided IPD (n¼ 1951 on topical NSAID), including 11 placebo-
controlled RCTs (n¼ 1587 on topical NSAIDs, 1553 on placebo). Seven potential predictors of re-
sponse were examined. Topical NSAIDs were superior to placebo [6 (95% CI 9, 4)], with a
small, but statistically significant greater effect in women than men [difference 4 (95% CI 8,
1)]. The overall treatment effect was 4-fold larger than the specific effect [25 (95% CI 31,
19)] and increased with greater baseline pain severity (P< 0.001). No differences in efficacy were
observed for age, BMI, features of inflammation, duration of complaints or radiographic OA
severity.
Conclusion. Topical NSAIDs are effective for OA pain relief. Greater overall pain relief in individuals
with more baseline pain might be due to contextual and non-specific effects, including regression to
the mean. Additional factors that have been linked either mechanistically or through empirical evidence
to outcomes should be selected for inclusion across future RCTs in order to facilitate the identification
of response predictors through IPD-MA.
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Rheumatology key messages
. Topical NSAIDs are effective for OA pain.
. No clinically significant predictors of the specific treatment response are available in published RCTs.
. Future RCTs should measure recognized peripheral/central risk factors for OA pain at baseline.
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Introduction
Pain is an important and distressing feature of OA and
the most common reason for OA-related visits to pri-
mary care [1]. Topical NSAIDs are recommended treat-
ments [2], which have been shown to be superior to
placebo in randomized controlled trials (RCTs) [3].
However, little is known regarding any patient-level
predictors of response to topical NSAIDs. Patient-level
predictors of response could improve clinical decision-
making by guiding optimal treatment selection for the in-
dividual patient at the time of assessment (precision
medicine).
Treatment effects can be defined as specific treat-
ment effects (i.e. the difference between treatment and
placebo, resulting from the biological effect of the treat-
ment itself) and overall treatment effects (i.e. the total
improvement from baseline, which includes the specific
effect, contextual effects from receiving a treatment and
non-specific effects such as temporal variation in symp-
tom severity) [4]. While the former is useful in demon-
strating the potential efficacy of a new treatment, the
latter explains the total benefits that an individual patient
may obtain from a treatment in clinical practice [5].
RCTs are mainly powered to show benefit over a com-
parator (either placebo or active) and, on their own, usu-
ally have insufficient power for robust subgroup analysis
or analysis of potential response predictors. Individual
patient data meta-analyses (IPD-MAs) involve the re-
examination of raw, de-identified patient-level data from
relevant RCTs, thus increasing the power relative to pri-
mary studies and overcoming widely recognized limita-
tions of aggregate data met-analyses (AD-MAs) [6].
Therefore IPD-MAs may identify clinically important re-
sponse predictors, which could prove useful in shared
decision-making with respect to treatment selection
based on individual patient characteristics. The aim of
the present study was to examine predictors of the spe-
cific and overall treatment effect of topical NSAIDs in
OA using an IPD-MA of RCTs.
Methods
Protocol and registration
The study is part of body of work, the protocol of which
is published [7] and available on PROSPERO (2016;
CRD42016035254). We were unable to conduct an IPD-
MA for topical capsaicin as pre-specified [7], as none of
the data custodians were willing or able to contribute
data (10 eligible RCTs). The present work therefore
examines only topical NSAIDs in OA.
Study selection
The process for study selection is available in the proto-
col [7] and is briefly described below. RCTs comparing
topical NSAIDs to any active or placebo comparator in
participants with OA were eligible [7]. RCTs had to
have a minimum duration of 1 week and report pain
outcomes. Trials were identified through systematic
literature searches (to November 2015) of six databases
(MEDLINE, Embase, Allied and Complementary
Medicine Database, Cumulative Index to Nursing and
Allied Health Literature, Web of Science and Cochrane
Library) and scrutiny of the reference lists of included
publications and MAs in the area (Supplementary mater-
ial, section Example literature search strategy, available
at Rheumatology online). In addition, unpublished RCTs
were sought from pharmaceutical companies that
manufacture topical NSAIDs for sale in the UK or that
have registered trials for the medications. Companies
were identified via the British National Formulary or elec-
tronic Medicines Compendium. Trial registrations were
searched via clinicaltrials.gov and clinicaltrialsregister.eu.
Approval from a research ethics committee was not
required, as the work involved analysis of de-identified
data and no new data collection was undertaken.
AD
AD extraction and risk of bias assessment were con-
ducted independently by two authors (M.S.M.P. and
J.S.). Data extracted included publication information,
trial design, participant demographics, interventions and
pain outcome data. Risk-of-bias assessment was con-
ducted using a modified Cochrane Risk of Bias tool [7,
8]. AD were used to determine whether the captured
IPD were representative of the published evidence base.
IPD collection and management
The first or corresponding author of all eligible trials was
contacted using a standardized e-mail, personalized to
include the author name and study details. Where no re-
sponse was received, additional attempts to contact
data custodians were made by sending two reminder e-
mails, contacting via letter and telephone, contacting all
other publication authors, contacting the institution
where the research was conducted and reaching out to
the trial funder or sponsor. Unless contact details were
unavailable, all additional approaches were implemented
for the studies until a definitive response (accepting or
declining collaboration) was received or data collection
was closed.
Data custodians that expressed an interest in collab-
oration were asked to sign a data transfer agreement
developed by the OA Trial Bank [9] or the University of
Nottingham outlining the terms for collaboration and
transfer of data.
Collaborators were given the option to share the
whole anonymized dataset or only the variables required
for analysis in the IPD-MA. Baseline variables sought
were pre-specified and are listed in Table 1. Baseline
and follow-up pain data at all durations of assessment
were collected. Where multiple assessments of pain
were available, visual analogue scale (VAS) global pain
scores were prioritized [3]. If unavailable, categorical
global pain scores, VAS pain during activity or disease-
specific composite tools were used instead [3]. The hier-
archical ordering of outcomes was specified a priori [7].
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On receiving the IPD, an initial screen of the data was
conducted to ensure that IPD for all randomized partici-
pants were received. Any discrepancies were discussed.
A consistent approach to coding, variable labelling,
standardization of variables and dichotomizing continu-
ous variables was established (Supplementary Table S1,
available at Rheumatology online). A study identifier was
given to each trial and participants retained their original
study-specific participant identifier. Pain scores were
standardized to a 0–100 scale within each study [10].
Analyses were based on two treatment effects: specif-
ic and overall treatment effects. Potential predictors of
both specific and overall treatment effects were exam-
ined. Person-level characteristics investigated were
those pre-specified in Table 1. These were chosen a pri-
ori as recognized peripheral and central risk factors of
OA or OA pain and were examined if available in more
than one RCT. Treatment effects are presented as the
difference between the treatment and placebo groups
(specific effect) or within the treatment arm (overall ef-
fect) on a 0–100 scale for pain. Only placebo-controlled
RCTs were used to examine the specific treatment ef-
fect, while all placebo- and active-controlled RCTs were
analysed for the overall treatment effect.
Statistical analysis
AD-MA
Published placebo-controlled RCTs were combined in a
random effects AD-MA for the specific and overall treatment
effects. Effect sizes (ESs) were calculated using Hedges’ g
[11]. ESs were back-translated to a 0–10 cm VAS [12] and
multiplied by 10 for direct comparison with the IPD-MA. As
the focus of the work was to examine patient-level predic-
tors of response, AD and IPD were not combined.
IPD-MA
IPD were analysed in a one-stage IPD-MA using pain
data at or nearest to 4 weeks of treatment (primary) [13,
14]. Secondary analyses were conducted using repeated
measures data during follow-up. Model specifications
for the one-stage IPD-MA were guided by assumptions
made in a two-stage IPD-MA setting: model fit and
computational efficiency.
The specific treatment effect was examined in a
mixed effects multilevel model, clustered at the study
level using a random trial intercept. Follow-up pain
scores were the dependent variable. Each trial was
given a separate adjustment term for baseline severity
and separate residual variances. A random effects distri-
bution was assumed for the treatment term. Potential
predictors of the specific effect were examined through
the addition of a stratified predictor term and a common
treatment-by-predictor interaction term. For computa-
tional efficiency, the predictor, treatment and treatment-
by-predictor interaction terms were assumed fixed. Two
interaction terms were included: a within-study inter-
action term (centred to the study mean) and an across-
study interaction term based on the study mean [13,
15]. The models were built using only one predictor and
interaction term per model and were adjusted only for
baseline pain. The parameters were estimated using the
restricted maximum likelihood approach.
The model for the overall treatment effect specified
separate residual variances per trial and included a ran-
dom trial intercept to account for clustering at the study
level. The model was developed using only the treat-
ment arm, thus a treatment term was not used. The
model was run using change-from-baseline pain scores
as the dependent variable and each potential prognostic
factor was entered individually as a covariate.
Significant predictors (P<0.05) were subsequently
examined in multivariable analysis (stratified per study).
Secondary and sensitivity analyses. Secondary analyses
were conducted using data from all durations of follow-up
(repeated measures). For this, the primary models were
extended to include multiple outcome data per participant
by clustering also at the participant level (random inter-
cept) and adjusting for week (fixed, common term).
A two-stage IPD-MA was conducted for sensitivity
analysis and to generate forest plots using ipdmetan
[16]. Linear regression models estimating the specific or
overall treatment effects were built within each trial and
subsequently pooled in a random effects MA.
All analyses were conducted in Stata software (version
15, StataCorp, College Station, TX, USA).
Risk of bias across studies
The quality of evidence was determined using Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) criteria [17], modified to capture
quality elements relevant for IPD-MAs (Supplementary
material, section GRADE modifications for IPD-MA,
available at Rheumatology online).
Results
Study selection and IPD obtained
IPD were sought for 63 RCTs of topical NSAIDs.
Responses were obtained for 46 (Fig. 1); of these, data
TABLE 1 Baseline data sought from data custodians
Participant ID
Date of randomization/inclusion
Age or date of birth
Sex
Weight
Height
BMI
Duration of complaints
Signs of inflammation—clinical (e.g. effusion) or biochemical
(e.g. ESR, CRP)
Nature of pain (dull/neuropathic)
Indicators of central sensitization
Psychological assessments (e.g. depression, anxiety,
catastrophizing)
Index joint
Radiographic OA severity
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were received for 15 RCTs (24%). The most common
reasons given for declining collaboration were not being
interested (11 RCTs), not being data custodian (8 RCTs)
and the IPD being unavailable or not found (9 RCTs).
Direct contact with pharmaceutical manufacturers of
topical NSAIDs (33 companies, including sponsors of
published trials) yielded no additional data. Data collec-
tion took 25 months from first contact to the last data
received.
Of 52 eligible RCTs available as full-text publications,
21 were analysed in the AD-MA. Reasons for exclusion
were no placebo group (22 RCTs), non-eligible partici-
pants (3 RCTs) and insufficient data available in publica-
tion for analysis (6 RCTs).
Of the 15 RCTs (1951 participants on topical NSAIDs)
with IPD included in this study, 11 were placebo con-
trolled (3140 participants: 1587 on topical NSAIDs and
1553 on placebo). Active controls used were chamomile
oil, SRL homeopathic gel, arnica montana gel, dwarf
elder gel and any oral NSAID. Checking the received
IPD confirmed that full datasets were received for 13 of
the 15 RCTs, whereas 2 [18, 19] provided data only for
participants who completed the trials. Across all RCTs,
6% and 5% of participants were missing primary pain
data for the specific and overall analyses, respectively.
Baseline demographics were balanced across partici-
pants with and without missing data, and complete case
analysis was used.
Characteristics of included studies and participants
The trial characteristics and intervention details for the
15 included RCTs were comparable to the 21 published
RCTs included in the AD-MA (Supplementary Tables
S2–S5, available at Rheumatology online). Assessments
for the risk-of-bias domains are available in the
Supplementary material, section Risk of bias, available
at Rheumatology online. Randomization was adequate
and fully described in 75% of the studies. This was the
domain with the lowest risk of bias. Three active-
controlled trials did not adequately blind participants or
trial personnel.
All trials were of parallel design and recruited
community-dwelling individuals (i.e. not hospital inpa-
tients) with OA. Twelve trials were for knee OA (75% of
the IPD-MA population) and three were for hand OA.
The RCTs were undertaken with participants predomin-
antly from the USA or Europe. Most (80%) trials
received funding by pharmaceutical companies, includ-
ing A.Vogel (BioForce AG), IBSA Institut Biochimique,
Inpellis, VSM and Novartis (a GlaxoSmithKline
company).
The majority of trials assessed an NSAID gel (79%),
although a patch [20, 21] or cream [22] was also used.
Diclofenac was the most commonly used topical NSAID,
but ibuprofen and piroxicam were also assessed. One
trial [23] did not specify which topical NSAID partici-
pants should use, but recommended they use
ibuprofen.
Approximately two-thirds of the study population were
women. The mean age was 62 years and, on average,
participants reported developing OA symptoms within
the preceding 3 years (Table 2).
Similarly, the AD-MA RCTs were all parallel design,
largely recruited community-dwelling individuals from
Europe or North America, were published over a similar
time period, were mainly funded by pharmaceutical
companies (71%) and most commonly assessed a top-
ical NSAID gel (52%). Two-thirds of the population were
women.
Specific treatment effect
Topical NSAIDs were statistically superior to placebo for
pain relief at or nearest to 4 weeks [6 (95% CI 9, 4)]
(Fig. 2). Specific treatment effect estimates were com-
parable to the AD-MA [21 RCTs; 6191 participants; 8
(95% CI 10, 5); Supplementary Fig. S1, available at
Rheumatology online]. The GRADE quality of evidence
was moderate, limited by potential data availability bias
FIG. 1 Flow chart of RCT identification, contact and ac-
quisition for IPD-MA of topical NSAIDs in OA
Monica S. M. Persson et al.
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(Supplementary Table S6, available at Rheumatology
online).
Overall treatment effect
Participants using topical NSAIDs experienced, on aver-
age, a 25-point (95% CI 31, 19) decrease in pain at or
nearest to 4 weeks (Fig. 3). A large variation in overall
treatment effect was observed. The GRADE quality of evi-
dence was deemed very low due to the study design, lack
of blinding of active-controlled trials, inconsistency and
potential data availability bias (Supplementary Table S7,
available at Rheumatology online). The AD-MA estimate of
the overall effect was marginally higher [21 RCTs; 3183
participants; 31 (95% CI 35, 27); Supplementary Fig.
S2, available at Rheumatology online].
Predictors of response
Of the pre-specified peripheral and central determinants
of OA and OA pain sought from RCTs, data were only
available for seven potential person-level determinants
of response (Table 3). Age, BMI, inflammation, symptom
duration and radiographic severity did not predict re-
sponse to topical NSAIDs. A statistically significant inter-
action was observed between treatment and sex in the
specific effect model (P¼0.023) (Supplementary Fig. S3,
available at Rheumatology online), with women reporting
greater reductions in pain than men [women: 7 (95%
CI 10, 5) vs men: 3 (95% CI 6, 1)].
Individuals with higher levels of pain at baseline
reported significantly greater pain relief after treatment
with topical NSAIDs (larger overall treatment effect,
P<0.001). For each 1-point increase in baseline pain,
participants experienced 0.53 more pain reduction.
Women also reported greater overall pain relief than
men (P¼0.008), but adjustment for baseline pain in mul-
tivariable analysis rendered the effect of sex non-
significant (P¼ 0.162). The association between baseline
pain and treatment effect remained significant
(P<0.001).
Additional analyses
Participants were followed up multiple times per trial,
generating 11 433 and 6494 observations for the sec-
ondary analyses of the specific and overall treatment
effects, respectively. Extension of the models to include
repeated measures yielded similar, but smaller, specific
[6 (95% CI 8, 4)] and overall [20 (95% CI 27,
12)] treatment effects. Using repeated measures data
in the specific effects model, the interaction between
treatment and sex did not reach statistical significance
[b for interaction: 3 (95% CI 6, 0); P¼0.066]. In the
overall effects model, findings for the association be-
tween sex, baseline pain and overall treatment effects
were comparable to the primary model (Supplementary
Table S8, available at Rheumatology online).
Two-stage IPD-MAs were in agreement with findings
from the one-stage models (Supplementary Tables S9
and S10, available at Rheumatology online).
Discussion
To our knowledge, this is the first IPD-MA conducted to
identify predictors of response to topical NSAIDs in OA.
Topical NSAIDs were statistically better than placebo for
TABLE 2 Baseline characteristics of participants
Baseline characteristic Specific effect trials (n5 11) Overall effect trials (n5 15)
n NSAID n Placebo n NSAID
Randomized, n 1587 1553 1951
Women, n (%) 1587 1077 (67.9) 1553 1085 (69.9) 1951 1324 (67.9)
Age, mean (S.D.), years 1587 62.7 (10.2) 1552 62.7 (10.4) 1951 62.5 (10.3)
Baseline pain (1–100 scale), mean (S.D.) 1586 68.0 (17.9) 1552 67.6 (18.0) 1948 65.0 (20.2)
BMI, mean (S.D.), kg/m2 1545 29.6 (6.2) 1516 29.7 (6.4) 1717 29.6 (6.1)
Weight, mean (S.D.), kg 1548 82.7 (19.4) 1518 82.6 (19.6) 1772 81.7 (19.1)
Inflammation (any) present, n (%) 1269 300 (23.6) 1238 271 (21.9) 1407 306 (21.8)
Clinical inflammation present, n (%) 836 152 (18.2) 825 143 (17.3) 974 158 (16.2)
Biochemical inflammation, n (%) per tertile 1151 1117 1141
Lowest tertile, n (%) 494 (42.9) 496 (44.4) 494 (42.9)
Middle tertile, n (%) 325 (28.2) 300 (26.9) 325 (28.2)
Highest tertile, n (%) 332 (28.8) 321 (28.7) 332 (28.8)
Knee joint affected, n (%) 1587 1187 (74.8) 1553 1170 (75.3) 1951 1,452 (74.4)
Hand joint affected, n (%) 1587 400 (25.2) 1553 383 (24.7)
Duration, median (IQR), months 152 25 (12–60) 152 27 (10–57) 136 30 (12–60)
Standardized radiographic severity, mean (S.D.) 1389 46.3 (15.2) 1360 45.4 (15.2) 184 45.4 (42.4)
Clinical signs of inflammation: presence of swelling and warmth (one study), presence of effusion (four studies).
Biochemical inflammation (divided into tertiles within each study with identical observations allocated to the same tertile
rank): ESR (one study), CRP (two studies). Standardized radiographic severity (0–100) calculated within each study from
Kellgren–Lawrence grade (0–4; seven studies), severity of changes (0–3; one study), number of changes (1–5; one study).
Predicting response to topical non-steroidal anti-inflammatory drugs in osteoarthritis
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OA pain (6 points on a 0–100 scale) and produced total
pain reductions from baseline, including placebo effects,
that were clinically significant (25 points improvement).
The results were consistent across different outcome
points (nearest to 4 weeks or repeated measures) and
IPD-MA approaches (one-stage and two-stage IPD-
MAs). Baseline pain predicted overall treatment effect,
but other patient-level factors measured in RCTs of top-
ical NSAIDs were not clinically meaningful predictors of
response. Future RCTs in OA should measure additional
patient characteristics that potentially may be of value
for stratification of responses.
We show that participants with higher pain at baseline
may report more pain relief than those with less pain at
baseline. However, no interaction was observed be-
tween baseline pain and topical NSAIDs for the specific
treatment effect, possibly indicating that baseline pain is
a prognostic factor for the contextual or non-specific
effects (such as the Hawthorn effect and regression to
the mean) of topical NSAIDs [24–26]. Previous study-
level evidence has shown an association between
increased baseline pain severity and increased context-
ual responses in OA [27]. The present IPD-MA extends
these findings to demonstrate that the majority of the
treatment effects of topical NSAIDs derive from context-
ual effects and that the magnitude of contextual effects
is dependent on baseline pain levels.
There is limited evidence for predictors of response to
topical NSAIDs and this is the first study to present pos-
sible sex-related differences in response. The difference
in specific response between the sexes was statistically
significant in our primary analysis, but the effect was
small and was not replicated when including data avail-
able for all measured time points. A difference in benefit
between women and men of 4 points on a 0–100 point
scale might not be clinically meaningful, and would not
justify targeting the treatment to women alone. Effects
of sex on overall treatment response might be explained
by baseline pain, which was overall worse in women
than men. No other measured patient-level factors sig-
nificantly interacted or associated with the treatment ef-
fect of topical NSAIDs.
Additional factors not reported in the selected RCTs
might better predict treatment outcomes. There is evi-
dence that indices of central sensitization, neuropathic-
like or nociceptive pain qualities, psychological factors
such as catastrophizing and negative affect, radiographic
OA severity or synovial inflammation associate with OA
FIG. 2 Specific treatment effect (0–100 scale) at or nearest to 4 weeks in two-stage IPD-MA. Effect presented as dif-
ference between topical NSAID and placebo on a 0–100 scale
Monica S. M. Persson et al.
6 https://academic.oup.com/rheumatology
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/doi/10.1093/rheum
atology/keaa113/5818943 by guest on 16 April 2020
FIG. 3 Overall treatment effect (0–100 scale) at or nearest to 4 weeks in two-stage IPD-MA. Effect presented as overall
treatment effect (change from baseline) on a 0–100 scale
TABLE 3 Potential predictors of the specific and overall treatment effect in one-stage IPD-MA
Predictor N Specific effect N Overall effect
n b (95% CI) n b (95% CI)
Sex (female¼1, male¼0) 11 2939 4.28 (7.98, 0.58) 15 1857 3.17 (5.53, 0.81)
Age, years 11 2938 0.06 (0.11, 0.22) 15 1857 0.02 (0.13, 0.09)
Baseline pain (0100) 11 2939 0.05 (0.06, 0.16) 15 1857 0.53 (0.59, 0.47)
BMI, kg/m2 10 2863 0.03 (0.27, 0.32) 12 1633 0.09 (0.12, 0.29)
Inflammation (yes¼1, no¼0) 7 2339 0.31 (4.98, 4.36) 8 1329 2.16 (5.42, 1.09)
Clinical 4 1550 1.84 (8.24, 4.55) 5 924 3.03 (7.40, 1.34)
Biochemical 6 2116 0.90 (1.53, 3.33) 6 1088 1.18 (0.55, 2.90)
Duration, months 3 280 0.04 (0.15, 0.07) 4 181 0.03 (0.09, 0.03)
XR severity (0–100) 7 2576 0.01 (0.12, 0.14) 9 1412 0.08 (0.00, 0.17)
b presented on a 0–100 scale. Significant interactions (specific effect) or associations (overall effect, unadjusted model) are
shown in bold. A negative interaction effect for sex (specific effect) indicates a greater specific effect for topical NSAIDs in
women relative to men. A negative association between sex and overall treatment effect indicates more pain reduction in
women relative to men. A negative association between baseline pain and overall treatment effect indicates that the higher
the baseline pain score, the more reduction in pain. b: beta-coefficient for interaction effect (specific effect) or covariate
(overall effect); n: number of participants; N: number of trials; XR: radiographic severity.
Predicting response to topical non-steroidal anti-inflammatory drugs in osteoarthritis
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pain progression [28–31] and therefore might predict re-
sponse to analgesic treatments in OA. In order to reduce
research waste and facilitate future research into predic-
tors of response, we suggest that all RCTs in OA should
assess these important patient-level characteristics at
baseline. These factors can be assessed by validated
questionnaires, such as painDETECT (neuropathic-like
pain features) [32], the Pain Catastrophizing Scale (cata-
strophizing) [33] and the Hospital Anxiety and Depression
Scale (negative affect) [34]. Structural severity and syn-
ovial inflammation could be assessed using a combin-
ation of plain film radiographs, MRI and ultrasound.
Central sensitization could be assessed using quantitative
sensory testing. Standardizing the measurement of a
core set of potentially important factors across RCTs
would ensure that future IPD-MAs are able to examine
factors that are of theoretical importance to identifying
predictors of response to analgesics.
We suggest that patients with knee and hand OA may
benefit from trying a topical NSAID, as overall treatment
effects are large and pain reduction is likely to be clinic-
ally significant. Topical NSAIDs may be considered in a
patient with OA, irrespective of their age, BMI, level of
inflammation, duration of complaints and radiographic
severity. Patients with more severe pain at baseline may
experience larger overall levels of pain relief and thus
warrant trying a topical NSAID before moving up the an-
algesic ladder. Finally, the difference in effect between
men and women is unlikely to be clinically significant,
and topical NSAIDs should continue to be offered equal-
ly irrespective of gender.
The present IPD-MA is subject to several limitations.
Only a subset of eligible studies were analysed and the
present work may therefore be subject to data availabil-
ity bias, reflected in the GRADE rating of quality [35].
However, the specific effect IPD-MA still included a
large pool of participants (n¼3140), and participant
characteristics and outcomes were similar in our IPD to
our AD-MA, suggesting that the included studies might
be representative of the eligible study pool. Although the
participant characteristics analysed were defined a pri-
ori, multiple covariates were examined and our examin-
ation of predictors should be viewed as exploratory. In
order to pool data, pain outcome scores were standar-
dized from their original scales to a 0–100 scale, as in
previous studies [10, 36], although the instruments might
have different measurement properties or sensitivities.
Data quality was not high, although quality downgrading
was partly due to analyses of the overall treatment with-
in one treatment arm, thereby making the data observa-
tional in nature. Our model specifications were guided
by assumptions made in the two-stage IPD-MA [14],
and this might have influenced the results. Due to model
complexity, assumptions were further limited by non-
convergence, and intention-to-treat analysis could not
be conducted because of model complexity.
In conclusion, topical NSAIDs are effective for OA
pain. People with higher OA pain at baseline experience
greater overall reductions in pain on using the treatment,
but this may be attributed to contextual or non-specific,
rather than specific, treatment effects. Other baseline
characteristics routinely reported in RCTs did not predict
clinically important differences in topical NSAID re-
sponse. Additional factors that have been linked either
mechanistically or through empirical evidence to out-
comes should be selected for inclusion across future
RCTs in order to facilitate the identification of response
predictors through IPD-MA. Such factors might include
recognized central and peripheral risk factors for OA
pain.
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